TQB-2029 / Sino Biopharm - LARVOL DELTA

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma (clinicaltrials.gov) - P1 | N=136 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma (clinicaltrials.gov) - P1 | N=136 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Two new drugs from China Biopharmaceuticals were approved for clinical trials for the first time, addressing the problem of drug resistance in malignant tumors [Google translation] (Sino Biopharm Press Release) - "Recently, two Class 1 new drugs of Sino Biopharmaceutical's subsidiary, TQB2029 for injection and TQB3002 tablets, were approved for clinical trials for the first time. They are intended to be used for the treatment of advanced malignant tumors and multiple myeloma, respectively, aiming to improve the drug resistance problem faced by current anticancer drugs."

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor